Jeroen C. Verheijen

Biochemical, Cellular, and <i>In vivo</i> Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Ker Yu, Lourdes Toral‐Barza, Celine Shi et al. · Cancer Research · 2009 · 326 citations

Chemoprevention Strategy, Cellular Pharmacology, Selective Inhibitors +22

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

Ker Yu, Celine Shi, Lourdes Toral‐Barza et al. · Cancer Research · 2010 · 208 citations · Full text

Antitumor Activity, Chemoprevention Strategy, Pharmacotherapy +22

ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines

Arie Zask, Jeroen C. Verheijen, Kevin J. Curran et al. · Journal of Medicinal Chemistry · 2009 · 98 citations · Full text

Chemical Biology, Pharmaceutical Chemistry, Tumor Biology +19

Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors

Arie Zask, Joshua A. Kaplan, Jeroen C. Verheijen et al. · Journal of Medicinal Chemistry · 2009 · 96 citations · Full text

Drug Target, Bioorganic Chemistry, Pharmacotherapy +17

Transition Metal Derivatives of Peptide Nucleic Acid (PNA) OligomersSynthesis, Characterization, and DNA Binding

Jeroen C. Verheijen, Gijsbert A. van der Marel, Jacques H. van Boom et al. · Bioconjugate Chemistry · 2000 · 85 citations